Skip to main content

Table 2 Cardiac function tests and treatments in the HF subjects

From: Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients

Variables

HF subjects (n=179)

Heart rate (bpm)

76.2±13.6

QRS complex (ms)

120 (98–160)

QTc interval (ms)

449.0 (414.0–478.5)

PR interval (ms)

172.9±29.2

Normal sinus ECG rhythm (%)

68

6MWT (m)

375 (250–450)

MLHFQ

38.6±24.1

LVEDD (mm)

63.5±11.6

LVESD (mm)

50.5±11.2

AI

46.1±9.8

Left ventricular ejection fraction (%)

32 (25–39)

NT-proBNP (pmol/L)

679.8 (405.5–1177.9)

ACE inhibitor (%)

65

β-blocker (%)

61

Diuretic (%)

78

Statin (%)

37

  1. Abbreviations: HF, heart failure; ECG, electrocardiogram; 6MWT, six-minute walk test; MLHFQ, Minnesota Living with Heart Failure Questionnaire; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; AI, aortic insufficiency; NT-proBNP, N-terminal fragment of pro-B-type natriuretic peptide; ACE, angiotensin-converting enzyme.
  2. The data are presented as the mean±SD or median (interquartile range), unless otherwise indicated.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840